Topic · page 4 of 6

Cardiometabolic & kidney

Diabetes, obesity, CKD and their cardiovascular or cardiorenal outcomes, SGLT2i/GLP-1 RA outside a primary HF population

Briefs 121–160 of 238 placed here, newest publication first

Briefs in Cardiometabolic & kidney

Newest publication first

Eur J Prev Cardiol11 Sep 2025
The association of haptoglobin levels and phenotype with cardiovascular disease in Type 2 diabetes: a Fenofibrate Intervention and Event Lowering in Diabetes sub-study
Secondary analysis
Eur J Prev Cardiol5 Sep 2025
Extracellular vesicle signature is associated with cardio-metabolic improvement after bariatric surgery
Cohort study
Eur J Prev Cardiol3 Sep 2025
Effect of incretin-based therapies on blood pressure: a systematic review and meta-analysis
Meta-analysis
Eur Heart J31 Aug 2025
Semaglutide promotes bone marrow–derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial
Randomised controlled trial
J Am Coll Cardiol27 Aug 2025
Anthropometric Measures, Cardiovascular Outcomes, and Treatment Effects of Finerenone in Cardiovascular-Kidney-Metabolic Disease: Pooled Participant-Level Analysis of 3 Global Trials
Meta-analysis
Lancet18 Aug 2025
Safety and efficacy of steroidal mineralocorticoid receptor antagonists in patients with kidney failure requiring dialysis: a systematic review and meta-analysis of randomised controlled trials
Meta-analysis
Lancet16 Aug 2025
Spironolactone in patients on chronic haemodialysis at high risk of adverse cardiovascular outcomes (ALCHEMIST): a multicentre, double-blind, randomised, placebo-controlled trial and updated meta-analysis
Meta-analysis
Lancet16 Aug 2025
Spironolactone versus placebo in patients undergoing maintenance dialysis (ACHIEVE): an international, parallel-group, randomised controlled trial
Randomised controlled trial
Eur J Heart Fail21 Jul 2025
Impact of Canagliflozin on Heart Stress and Outcomes: Pooled Insights from CREDENCE and CANVAS
Secondary analysis
Eur J Prev Cardiol17 Jul 2025
Association between the life's essential 8 health behaviors and prognosis in patients with advanced cardiovascular-kidney-metabolic syndrome
Cohort study
Eur J Prev Cardiol15 Jul 2025
Expert perspectives on incorporating glucagon-like peptide-1 receptor agonist in diabetes and chronic kidney disease: challenges and opportunities
Guideline or statement
Eur J Prev Cardiol30 Jun 2025
Hepatic steatosis in cardiovascular–kidney–metabolic syndrome: fatty liver Index as a predictor of cardiovascular outcomes
Cohort study
JACC Heart Fail26 Jun 2025
Linking Chronic Kidney Disease to Incident Heart Failure and Adverse Cardiac Remodeling Through the Plasma Proteome: The ARIC Study
Cohort study
Eur J Prev Cardiol13 Jun 2025
Estimating the health impact of menu calorie labelling policy and sugar-sweetened beverage taxation in two European countries: a microsimulation study
Research article
Eur J Prev Cardiol12 Jun 2025
Steatotic liver disease as a risk enhancer in the presence of metabolic syndrome
Cohort study
Circulation7 Jun 2025
A Nationwide Factorial Randomized Trial of Electronic Nudges to Patients With Chronic Kidney Disease and Their General Practices for Increasing Guideline-Directed Medical Therapy: The NUDGE-CKD Trial
Randomised controlled trial
Eur Heart J14 May 2025
Adult-onset type 1 diabetes: predictors of major cardiovascular events and mortality
Cohort study
Eur J Prev Cardiol13 May 2025
New diagnosis of diabetes in patients with myocardial infarction or stroke: a systematic review and meta-analysis
Meta-analysis
Eur J Heart Fail4 May 2025
Association Between Liver Fibrosis, Plasma Volume Status, and Cardiovascular Mortality: The Hiroshima Study on Glucose Metabolism and Cardiovascular Diseases
Cohort study
Eur J Prev Cardiol28 Apr 2025
Nocturnal hypoxaemic burden is associated with incident major adverse cardiovascular events in patients with type 2 diabetes
Cohort study
Eur Heart J22 Apr 2025
Incident hyperkalaemia risk model in chronic kidney disease and diabetes: the FIDELITY programme
Diagnostic or prognostic study
Eur J Prev Cardiol8 Apr 2025
Intensive systolic blood pressure control in patients with or without worsening renal function
Secondary analysis
J Am Coll Cardiol30 Mar 2025
Effects of Tirzepatide in Type 2 Diabetes: Individual Variation and Relationship to Cardiometabolic Outcomes
Meta-analysis
N Engl J Med29 Mar 2025
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
Randomised controlled trial
Lancet29 Mar 2025
Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial
Randomised controlled trial
Eur J Prev Cardiol21 Mar 2025
Multi-modal interventions outperform nutritional or exercise interventions alone in reversing metabolic syndrome: a systematic review and network meta-analysis
Meta-analysis
Eur J Prev Cardiol18 Mar 2025
Effect of sodium-glucose cotransporter-2 inhibitors on kidney outcomes of individuals with type 2 diabetes according to blood pressure levels
Cohort study
Eur J Prev Cardiol14 Mar 2025
Colchicine mitigates arterial stiffness in high-risk patients with type 2 diabetes: a randomized placebo-controlled trial
Randomised controlled trial
Nat Med7 Feb 2025
Telemedicine-supported lifestyle intervention for glycemic control in patients with CHD and T2DM: multicenter, randomized controlled trial
Randomised controlled trial
Eur J Prev Cardiol6 Feb 2025
Association of muscle-strengthening and aerobic physical activity with all-cause, cardiovascular disease, and cancer mortality in US adults with diabetes
Cohort study
Eur J Prev Cardiol23 Jan 2025
Arterial stiffness mediates insulin resistance-related risk of atherosclerotic cardiovascular disease: a real-life, prospective cohort study
Cohort study
Eur J Heart Fail23 Jan 2025
Canagliflozin Reduces Oral Loop Diuretic Intensification in Patients with Type 2 Diabetes: A Participant-Level Pooled Analysis of the CANVAS and CREDENCE Trials
Meta-analysis
Eur J Heart Fail17 Jan 2025
Efficacy and Safety of Finerenone in Patients with Chronic Kidney Disease and Type 2 Diabetes By Diuretic Use: A FIDELITY Analysis
Meta-analysis
Eur J Heart Fail14 Jan 2025
Unlocking the Power of Empagliflozin: Rescuing Inflammation in Hyperglycaemia-Exposed Human Cardiomyocytes Through Comprehensive Multi-Level Analysis
Mechanistic study
Eur J Heart Fail10 Jan 2025
Heart Failure Outcomes Captured by Adverse Event Reporting in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Observations from the VERTIS CV Trial
Secondary analysis
Circulation26 Dec 2024
Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via Modified Delphi Approach
Guideline or statement
Eur J Heart Fail5 Dec 2024
The Global Burden of Disease Attributable to High Body Mass Index in 204 Countries and Territories from 1990 to 2021 with Projections to 2050: An Analysis of the Global Burden of Disease Study 2021
Research article
J Am Coll Cardiol3 Dec 2024
2-Fold More Cardiovascular Disease Events Decades Before Type 2 Diabetes Diagnosis: A Nationwide Registry Study
Case-control study
J Am Coll Cardiol15 Nov 2024
Intensive Lifestyle Intervention, Cardiac Biomarkers, and Cardiovascular Outcomes in Diabetes: Look AHEAD Cardiac Biomarker Ancillary Study
Secondary analysis
Eur J Heart Fail9 Oct 2024
Cardiovascular Outcomes with Exenatide in Type 2 Diabetes According to Ejection Fraction: The EXSCEL Trial
Secondary analysis

All 238 Briefs in ExploreShowing Briefs 121–160 of 238, newest first